MAVORIXAFOR - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for mavorixafor and what is the scope of patent protection?
Mavorixafor
is the generic ingredient in one branded drug marketed by X4 Pharms and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Mavorixafor has forty-seven patent family members in eighteen countries.
One supplier is listed for this compound.
Summary for MAVORIXAFOR
| International Patents: | 47 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 5 |
| Patent Applications: | 517 |
| What excipients (inactive ingredients) are in MAVORIXAFOR? | MAVORIXAFOR excipients list |
| DailyMed Link: | MAVORIXAFOR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MAVORIXAFOR
Generic Entry Date for MAVORIXAFOR*:
Constraining patent/regulatory exclusivity:
TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS) Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MAVORIXAFOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| X4 Pharmaceuticals | Phase 1 |
| X4 Pharmaceuticals | Phase 3 |
| X4 Pharmaceuticals | Phase 2 |
US Patents and Regulatory Information for MAVORIXAFOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | 10,548,889 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MAVORIXAFOR
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 281082 | תכשירים של מעכבי cxcr4 ושיטות להכנה ושימוש (Compositions of cxcr4 inhibitors and methods of preparation and use) | ⤷ Subscribe |
| European Patent Office | 3843720 | COMPOSITIONS D'INHIBITEURS DE CXCR4 ET MÉTHODES DE PRÉPARATION ET D'UTILISATION (COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE) | ⤷ Subscribe |
| Slovenia | 3393468 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
